mtorc1 kinase inhibitor rmc-5552
Generic: mTORC1 Kinase Inhibitor RMC-5552
mtorc1 kinase inhibitor rmc-5552: 2 clinical trials tracked.
mtorc1 kinase inhibitor rmc-5552 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mtorc1 kinase inhibitor rmc-5552, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Primary endpoint: Maximum Tolerated Dose (MTD) (Cohort A)
Interventionalopen7 targetStarted 2023-04Completion 2025-121 site · United StatesNicholas Butowski
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors
Primary endpoint: Number of participants with adverse events (AEs)
Interventionalopen58 enrolledStarted 2021-04Completion 2024-068 sites · United StatesRevolution Medicines, Inc.